Bucillamine

Summary

Bucillamine (CHEMBL80830) is a phase-3 clinical-stage small molecule (ATC M01CC02); indicated across 5 conditions including rheumatoid arthritis and rheumatic disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: M01CC02
• Indications: 5 conditions
• Clinical trials: 5
• Chemistry: 223.3 Da · C7H13NO3S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL80830
Name	Bucillamine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	656604
ATC	M01CC02
Molecular formula	C7H13NO3S2
Molecular weight	223.3
InChIKey	VUAFHZCUKUDDBC-BYPYZUCNSA-N

SMILES: CC(C)(C(=O)N[C@@H](CS)C(=O)O)S

IUPAC name: (2R)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid

Also known as: Bucilamina, Bucilant, Bucillamine, BUCILLAMINE, SID144206698, bucillamine

Patent coverage: 1,009 distinct patent families (3,828 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
rheumatic disorder	3	MONDO:0005554	EFO:0005755
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
gout	2	MONDO:0005393	EFO:0004274
cystinuria	2	MONDO:0009067	MONDO:0009067

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00716248	PHASE4	UNKNOWN	Bucillamine Study of Holding Remission After Infliximab Dose-off
NCT02373202	PHASE3	COMPLETED	A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
NCT04504734	PHASE3	TERMINATED	Bucillamine in Treatment of Patients With COVID-19
NCT02330796	PHASE2	COMPLETED	Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
NCT02942420	PHASE2	UNKNOWN	Bucillamine Phase 2 Trial in Patients With Cystinuria

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).